Fulgent Genetics (NASDAQ:FLGT) Issues FY24 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY24 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $0.33 for the period, compared to the consensus estimate of ($0.39). Fulgent Genetics also updated its FY 2024 guidance to 0.330-0.330 EPS.

Fulgent Genetics Price Performance

FLGT opened at $19.43 on Friday. Fulgent Genetics has a one year low of $18.76 and a one year high of $30.68. The business has a 50 day simple moving average of $21.01 and a two-hundred day simple moving average of $21.43. The firm has a market capitalization of $588.67 million, a price-to-earnings ratio of -3.52 and a beta of 1.51.

Insider Activity at Fulgent Genetics

In other news, CEO Ming Hsieh sold 2,313 shares of Fulgent Genetics stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $52,805.79. Following the sale, the chief executive officer now owns 707,275 shares of the company’s stock, valued at approximately $16,147,088.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 4,324 shares of company stock worth $98,717 over the last quarter. Corporate insiders own 31.76% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.